These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2700994)

  • 21. Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.
    Green WR; Nowinski RC; Henney CS
    J Immunol; 1980 Aug; 125(2):647-55. PubMed ID: 6156211
    [No Abstract]   [Full Text] [Related]  

  • 22. Prolonged survival of AKR mice following allogeneic bone marrow transplantation.
    Rose WC; Bortin MM; Saltzstein EC
    Experientia; 1974 Sep; 30(9):1085-6. PubMed ID: 4153447
    [No Abstract]   [Full Text] [Related]  

  • 23. Spontaneous antilymphoma reaction of preleukaemic AKR mice is a non-T-cell killing.
    Gomard E; Leclerc JC; Levy JP
    Nature; 1974 Aug; 250(5468):671-3. PubMed ID: 4854374
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlations of in vivo growth of CTL-susceptible and -resistant variant tumor cell lines in CTL-responder AKR.H-2b:Fv-1b and -nonresponder AKR.H-2b mice.
    Azuma H; Wegmann KW; Green WR
    Cell Immunol; 1988 Oct; 116(1):123-34. PubMed ID: 3262427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-related changes in cell surface antigens of preleukemic AKR thymocytes.
    Kawashima K; Ikeda H; Stockert E; Takahashi T; Old LJ
    J Exp Med; 1976 Jul; 144(1):193-208. PubMed ID: 180229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of anti-MuLV cytotoxic T lymphocytes in the AKR.H-2b and AKR.H-2b:Fv-1b mouse strains.
    Wegmann KW; Blank KJ; Green WR
    Cell Immunol; 1988 May; 113(2):308-19. PubMed ID: 2834071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71.
    Schwarz H; Ihle JN; Wecker E; Fischinger PJ; Thiel HJ; Bolognesi DP; Schäfer W
    Virology; 1981 Jun; 111(2):568-78. PubMed ID: 6264673
    [No Abstract]   [Full Text] [Related]  

  • 28. Marked histoincompatibility between and within sublines of AKR mice used in a syngeneic leukemia model.
    Graff RJ; Valeriote F; Medoff G
    J Natl Cancer Inst; 1975 Oct; 55(4):1015-6. PubMed ID: 1102719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The in vitro generation of H-2-restricted cytotoxic T cells to AKR/Gross leukemia virus-induced tumors. I. Requirement for stimulation with allogeneic leukemia cells in vivo.
    Green WR
    J Immunol; 1982 Mar; 128(3):1043-9. PubMed ID: 6976986
    [No Abstract]   [Full Text] [Related]  

  • 30. AKR mouse leukemic cells in tissue culture. II. Immunologic studies on the AKR 87 cell line.
    Duś D; Harlozińska A; Skriabin A; Richter R
    Arch Immunol Ther Exp (Warsz); 1976; 24(5):727-40. PubMed ID: 187141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4-CD8+ T lymphocytes mediate AKR/gross murine leukemia virus nonresponsiveness in moderately aged AKR.H-2b:Fv-1b mice.
    Rich RF; Fujii T; Green WR
    J Immunol; 1992 May; 148(9):2961-7. PubMed ID: 1349325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of oncogenicity of tumour cells by DNA-mediated gene transfer.
    Hui K; Grosveld FG
    Haematol Blood Transfus; 1987; 31():261-2. PubMed ID: 3443392
    [No Abstract]   [Full Text] [Related]  

  • 33. Amplified expression of murine leukemia virus (MuLV)-coded antigens on thymocytes and leukemia cells of AKR mice after infection by dualtropic (MCF) MuLV.
    O'Donnell PV; Nowinski RC; Stockert E
    Virology; 1982 Jun; 119(2):450-64. PubMed ID: 6177096
    [No Abstract]   [Full Text] [Related]  

  • 34. Biologic effects of the altered MHS profile on the K36 tumor, a spontaneous leukemia of AKR.
    Festenstein H; Schmidt W; Testorelli C; Marelli O; Simpson S
    Transplant Proc; 1980 Mar; 12(1):25-8. PubMed ID: 7368290
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of H-2-linked immune responses involved in resistance to AKR tumor growth.
    Zalman MA; Meruelo D
    Immunogenetics; 1986; 24(1):51-62. PubMed ID: 2874112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo or in vitro treatments with anti-I-J alloantisera abolish immunity to AKR leukemia.
    Meruelo D; Flieger N; Smith D; McDevitt HO
    Proc Natl Acad Sci U S A; 1980 Apr; 77(4):2178-82. PubMed ID: 6769122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of CTL-defined, AKR/Gross retrovirus-associated tumor antigens by normal spleen cells: control by Fv-1, H-2, and proviral genes and effect on antiviral CTL generation.
    Green WR
    J Immunol; 1986 Jan; 136(1):308-12. PubMed ID: 2999246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunologic studies on Graffi-virus-infected spontaenous Gross leukemia of AKR mice.
    Micheel B; Pasternak G
    Int J Cancer; 1968 Sep; 3(5):603-13. PubMed ID: 4302083
    [No Abstract]   [Full Text] [Related]  

  • 40. Suppression of Gross leukemia cell-surface antigens: a kind of antigenic modulation.
    Aoki T; Johnson PA
    J Natl Cancer Inst; 1972 Jul; 49(1):183-92. PubMed ID: 5037434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.